Jean Jacques Bienaime

Director

Jean Jacques Bienaime (Director) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 1 sale), most often in Immunome, Inc. (IMNM). Across 3 priced purchase filings, the average 21-session return was +5.7% from execution and +7.2% from disclosure (delay-adjusted; derived). The largest single filing was $493K of ASND (2,000 sh across 2 lots, as filed), executed Aug 14.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

+5.7%

avg across 3 priced filings

Delay-adjustediThe same average, entered at disclosure dates

+7.2%

same 3 filings, from disclosure

Filings, ttm

3 buys · 1 sells

Median delay

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$907K

shares × price, as filed

Last traded

Aug 14

Filed Aug 18

Median ADV $31.5M across their filed names

Open performance→

Volume by month

Buys $713K Sells $194K

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 4 filings

Sector per market data · by filing · past 12 months

Most traded names

IMNM

Immunome, Inc. IMNM · 2 buys · 1 sell 2 filings ASND

Ascendis Pharma A/S ASND · 1 buy · 0 sells 1 filing

Recent filings

ASNDPURCHASE Ascendis Pharma A/S View filing → $493K
2,000 sh across 2 lots
Exec Aug 14
Filed Aug 18 · 9:02 PM ET IMNMSALE Immunome, Inc. View filing → $194K
10,000 sh × $19.41
Exec Jun 5
Filed Jun 9 · 5:30 PM ET IMNMPURCHASE Immunome, Inc. View filing → $117K
6,000 sh × $19.48
Exec Jun 5
Filed Jun 9 · 5:40 PM ET IMNMPURCHASE Immunome, Inc. View filing → $104K
5,000 sh × $20.70
Exec May 15
Filed May 19 · 7:56 AM ET